Publication:
Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses

dc.contributor.authorBeltran-Pavez, Carolina
dc.contributor.authorBontjer, Ilja
dc.contributor.authorGonzalez-Fernandez, Nuria
dc.contributor.authorPernas, Maria
dc.contributor.authorMerino-Mansilla, Alberto
dc.contributor.authorOlvera, Alex
dc.contributor.authorMiró, José María
dc.contributor.authorBrander, Christian
dc.contributor.authorAlcamí, José
dc.contributor.authorSanders, Rogier W
dc.contributor.authorSanchez-Merino, Victor
dc.contributor.authorYuste, Eloisa
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderPlan Nacional de I+D+i (España)
dc.contributor.funderFondation Martin Bodmeres_ES
dc.contributor.funderMinisterio de Economía, Industria y Competitividad (España)
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderConsejo Superior de Investigaciones Científicas (España)
dc.contributor.funderUnited States Department of Health and Human Services
dc.date.accessioned2022-05-17T08:00:21Z
dc.date.available2022-05-17T08:00:21Z
dc.date.issued2022-01-12
dc.description.abstractLongitudinal studies in HIV-1 infected individuals have indicated that 2-3 years of infection are required to develop broadly neutralizing antibodies. However, we have previously identified individuals with broadly neutralizing activity (bNA) in early HIV-1 infection, indicating that a vaccine may be capable of bNA induction after short periods of antigen exposure. Here, we describe 5 HIV-1 envelope sequences from individuals who have developed bNA within the first 100 days of infection (early neutralizers) and selected two of them to design immunogens based on HIV-1-Gag virus like particles (VLPs). These VLPs were homogeneous and incorporated the corresponding envelopes (7 to 9μg of gp120 in 1010 VLPs). Both envelopes bound to well-characterized bNAbs, including trimer-specific antibodies (PGT145, VRC01 and 35022). For immunogenicity testing, we immunized rabbits with the Env-VLPs or with the corresponding stabilized soluble Envelope trimers. A short immunization protocol (105 days) was used to recapitulate the early nAb induction observed after HIV-1 infection in these two individuals. All VLP and trimeric Envelope immunogens induced a comparably strong anti-gp120 response, despite having immunized rabbits with 30 times less gp120 in the case of the Env-VLPs. In addition, animals immunized with VLP-formulated Envs induced antibodies that cross-recognized the corresponding soluble stabilized trimer and vice versa, even though no neutralizing activity was observed. Nevertheless, our data may provide a new platform of immunogens, based on HIV-1 envelopes from patients with early broadly neutralizing responses, with the potential to generate protective immune responses using vaccination protocols similar to those used in classical preventive vaccines. Importance: It is generally accepted that an effective HIV-1 vaccine should be able to induce broad-spectrum neutralizing antibodies. Since most of these antibodies require long periods of somatic maturation in vivo, several groups are developing immunogens, based on the HIV envelope protein, that require complex and lengthy immunization protocols that would be difficult to implement to the general population. Here, we show that rabbits immunized with new envelopes (VLP-formulated) from two individuals who demonstrated broadly neutralizing activity very early after infection, induced specific HIV-1 antibodies after a short immunization protocol. This evidence provides the basis for generating protective immune responses with classic vaccination protocols with vaccine prototypes based on HIV envelope sequences from individuals who have developed early broadly neutralizing responses.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis project received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 681137 to I.B., N.G., A.O., C.B., J.A., R.W.S., and E.Y. It was also partially supported by the Spanish AIDS Research Network (RIS), funded by the Instituto de Salud Carlos III and co-funded by the European Regional Development Fund (ERDF) “A way to build Europe” (projects RD16CIII/0002/0001, RD16CIII/0002/0005, and RD16CIII/0025/0041), Plan Estatal de I1D1I 2013-2016 to N.G., A.M.M., J.A., V.S.M., E.Y., M.P., A.O., and C.B.; by IDIBAPS to J.M.M. (80:20 Research grant); by the Fondation Dormeur, Vaduz to C.B.; by the Ministerio de Economía, Industria y Competitividad to N.G., V.S.M., and E.Y. (PI17CIII/00049); by the Ministerio de Ciencia e Innovación to N.G., V.S.M., and E.Y. (PI20CIII/00039); by the Consejo Nacional de Innovación, Ciencia y Tecnología to C.B.P.; and by the HHS/ National Institutes of Health (NIH) to C.B. (P01-AI131568).es_ES
dc.format.number1es_ES
dc.format.pagee0134321es_ES
dc.format.volume96es_ES
dc.identifier.citationJ Virol. 2022 Jan 12;96(1):e0134321.es_ES
dc.identifier.doi10.1128/JVI.01343-21es_ES
dc.identifier.e-issn1098-5514es_ES
dc.identifier.journalJournal of virologyes_ES
dc.identifier.pubmedID34668778es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14398
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiology (ASM)
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI20CIII/00039es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI17CIII/00049es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0001es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0005es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0025/0041es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/681137/EUes_ES
dc.relation.publisherversionhttps://doi.org/10.1128/JVI.01343-21es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIV-1es_ES
dc.subjectNeutralizing antibodieses_ES
dc.subjectVaccineses_ES
dc.subjectVirus-like particleses_ES
dc.titlePotent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responseses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication81f03362-0e5b-4de5-8a58-33967ef255ba
relation.isAuthorOfPublicationcca7e901-0913-4b71-8c9d-ee7dd20b6458
relation.isAuthorOfPublication61e8a622-e8b9-409f-8005-eaf806da40b6
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication2c8533e8-d63c-4c22-9a9b-b630525f7153
relation.isAuthorOfPublication1e723484-61b4-4f8f-ad19-48873c9050f5
relation.isAuthorOfPublication.latestForDiscovery81f03362-0e5b-4de5-8a58-33967ef255ba
relation.isFunderOfPublicationa418cf3b-f427-4376-a75f-01dba9bb944f
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication0e5401ef-8ce7-439f-85e0-4e3550b5fade
relation.isFunderOfPublication780d850b-a444-4474-ba4e-85ab2579d4ac
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublication811243fc-9fda-46b1-b312-9259d8c570f6
relation.isFunderOfPublication6081a0d0-d423-4510-b1af-a52eac0c92e4
relation.isFunderOfPublication.latestForDiscoverya418cf3b-f427-4376-a75f-01dba9bb944f
relation.isPublisherOfPublication30cd8aef-e018-40d1-b05e-19af778995bd
relation.isPublisherOfPublication.latestForDiscovery30cd8aef-e018-40d1-b05e-19af778995bd

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PotentInductionOfEnvelope_2022.pdf
Size:
3.63 MB
Format:
Adobe Portable Document Format
Description: